Aligos discontinues development of its antisense oligonucleotide drug candidate ALG-020572 in subjects with chronic hepatitis B and pivots internal strategic emphasis to its small molecule portfolio
Shutterstock
Share:
- Dosing in the first cohort discontinued after multiple reports of ALT flares suggestive of drug-induced liver toxicity
- Funds will be redirected to support ongoing clinical programs, including ALG-000184 (Class-II CAM for CHB) and ALG-055009 (THR- agonist for NASH), and to accelerate internal oral small molecule development programs, including a SARS-CoV-2 protease inhibitor, a Class-I CAM for CHB and a PD-L1 inhibitor for CHB
Read the full press release here.
Source : Aligos Therapeutics, Inc.
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.